Side-by-side comparison of AI visibility scores, market position, and capabilities
Video game publisher with $5.5B revenue; Grand Theft Auto and NBA 2K franchises with Zynga mobile gaming positioning for GTA VI launch competing with EA and Activision Blizzard.
Take-Two Interactive Software is a leading American video game company producing some of the most commercially successful and critically acclaimed video game franchises — Grand Theft Auto (Rockstar Games), NBA 2K (2K Sports), BioShock, Borderlands, Civilization (through 2K Games), Red Dead Redemption, and mobile gaming through Social Point and Zynga (acquired in 2022 for $12.7 billion). Listed on NASDAQ (NASDAQ: TTWO) and headquartered in New York City, Take-Two generates approximately $5.5 billion in annual revenue.\n\nTake-Two's publishing portfolio is built around two studio groups: Rockstar Games (Grand Theft Auto franchise, Red Dead Redemption — both enormously profitable) and 2K Games (Borderlands, BioShock, Civilization, NBA 2K, Mafia, WWE 2K). The Grand Theft Auto franchise is among the most profitable entertainment properties in history — GTA V (2013) has sold over 200 million copies and GTA Online continues generating live service revenue over a decade post-launch. GTA VI, in development since 2020, is the most anticipated game release in the industry.\n\nIn 2025, Take-Two is in a pivotal period dominated by the GTA VI launch — the game is expected to be the highest-grossing entertainment launch in history. The company has been managing high development costs and debt from the Zynga acquisition (which gave Take-Two a major mobile gaming platform but at a premium price that has pressured the balance sheet). Take-Two competes with Electronic Arts, Activision Blizzard (Microsoft), and Sony PlayStation Studios for premium video game market share. The 2025 strategy is essentially defined by the GTA VI launch, with the Zynga mobile gaming portfolio providing recurring revenue while the industry awaits the next generation of console hits.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.